Michael R. Megna - Mar 21, 2022 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Mar 21, 2022
Transactions value $
-$12,298
Form type
4
Date filed
3/23/2022, 04:30 PM
Previous filing
Oct 6, 2021
Next filing
Apr 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +3.23K +82.21% 7.16K Mar 21, 2022 Direct F1
transaction KNSA Class A Common Share Tax liability -$12.3K -1.12K -15.64% $10.98 6.04K Mar 21, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -3.23K -100% $0.00* 0 Mar 21, 2022 Class A Common Share 3.23K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs.